Abstract
Background/Aims: OVE26 (OVE) mice provide a valuable model of advanced diabetic nephropathy (DN), but they take 8 months to develop moderate interstitial fibrosis and reduced glomerular filtration rate (GFR). The aim of this project was to produce a more rapid and advanced model of DN. Methods: Uninephrectomy was applied to OVE and FVB mice at 2 months of age. Albuminuria, GFR, glomerulosclerosis, interstitial fibrosis, gene expression and monocyte infiltration were evaluated as a function of diabetes and uninephrectomy. Results: Albuminuria, monocyte infiltration, mesangial matrix expansion and renal fibrosis were greatly accelerated in uninephrectomized mice. DN was more advanced 10 weeks after uninephrectomy than in untreated OVE mice at 8 months of age. Uninephrectomy had almost no effect on these characteristics in non-diabetic mice. Microarray studies indicated that the accelerated fibrosis and cell infiltration in nephrectomized OVE mice were accompanied by corresponding gene expression changes in canonical pathways for fibrosis and inflammation. Conclusion: Uninephrectomy greatly accelerates all features of diabetic renal damage. This procedure provides a 10-week period after surgery to examine very large changes in the pathology of DN. The model may be particularly useful for testing new therapies and for analysis of the progression of albuminuria and fibrosis in DN.
Journal Section:
Original Paper
References
1.
Breyer MD, Qi Z, Tchekneva E: Diabetic nephropathy: leveraging mouse genetics. Curr Opin Nephrol Hypertens 2006;15:227–232.
[PubMed]
2.
Breyer MD: Stacking the deck for drug discovery in diabetic nephropathy: in search of an animal model. J Am Soc Nephrol 2008;19:1623–1624.
[PubMed]
3.
Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson MA, Johnson RJ, Croker B: Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007;18:539–550.
[PubMed]
4.
Kanetsuna Y, Takahashi K, Nagata M, Gannon MA, Breyer MD, Harris RC, Takahashi T: Deficiency of endothelial nitric oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol 2007;170:1473–1484.
[PubMed]
5.
Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K, Takahashi N, Takahashi T: Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009;20:2503–2512.
[PubMed]
6.
Zheng S, Noonan WT, Metreveli NS, Coventry S, Kralik PM, Carlson EC, Epstein PN: Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 2004;53:3248–3257.
[PubMed]
7.
Zheng S, Carlson EC, Yang L, Kralik PM, Huang Y, Epstein PN: Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. J Am Soc Nephrol 2008;19:2077–2085.
[PubMed]
8.
Levine DZ, Iacovitti M, Robertson SJ, Mokhtar GA: Modulation of single-nephron GFR in the db/db mouse model of type 2 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 2006;290:R975–R981.
[PubMed]
9.
Ninichuk V, Kulkarni O, Clauss S, Anders HJ: Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy. Eur J Med Res 2007;12:351–355.
[PubMed]
10.
Dworkin LD, Hostetter TH, Rennke HG, Brenner BM: Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. J Clin Invest 1984;73:1448–1461.
[PubMed]
11.
Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris RC, Fogo AB, Breyer MD: Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. AmJ Physiol Renal Physiol 2004;286:F590–F596.
[PubMed]
12.
Dunn SR, Qi Z, Bottinger EP, Breyer MD, Sharma K: Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 2004;65:1959–1967.
[PubMed]
13.
Hartner A, Eifert T, Haas CS, Tuysuz C, Hilgers KF, Reinhardt DP, Amann K: Characterization of the renal phenotype in a mouse model of Marfan syndrome. Virchows Arch 2004;445:382–388.
[PubMed]
14.
Sanden SK, Wiggins JE, Goyal M, Riggs LK, Wiggins RC: Evaluation of a thick and thin section method for estimation of podocyte number, glomerular volume, and glomerular volume per podocyte in rat kidney with Wilms’ tumor-1 protein used as a podocyte nuclear marker. J Am Soc Nephrol 2003;14:2484–2493.
[PubMed]
15.
Ziyadeh FN, Hoffman BB, Han DC, Iglesias-de la Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015–8020.
[PubMed]
16.
Chen S, Hong SW, Iglesias-de la Cruz MC, Isono M, Casaretto A, Ziyadeh FN: The key role of the transforming growth factor-β system in the pathogenesis of diabetic nephropathy. Ren Fail 2001;23:471–481.
[PubMed]
17.
Qi Z, Breyer MD: Measurement of glomerular filtration rate in conscious mice. Methods Mol Biol 2009;466:61–72.
[PubMed]
18.
Eisner C, Faulhaber-Walter R, Wang Y, Leelahavanichkul A, Yuen PS, Mizel D, Star RA, Briggs JP, Levine M, Schnermann J: Major contribution of tubular secretion to creatinine clearance in mice. Kidney Int 2010;77:519–526.
[PubMed]
19.
Powell DW, Bertram CC, Cummins TD, Barati MT, Zheng S, Epstein PN, Klein JB: Renal tubulointerstitial fibrosis in OVE26 type 1 diabetic mice. Nephron Exp Nephrol 2009;111:e11–e19.
[PubMed]
20.
Vieyra MB, Heeger PS: Novel aspects of complement in kidney injury. Kidney Int 2010;77:495–499.
[PubMed]
21.
Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004;65:116–128.
[PubMed]
22.
Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 2004;19:2987–2996.
[PubMed]
23.
Schmid H, Boucherot A, Yasuda Y, Henger A, Brunner B, Eichinger F, Nitsche A, Kiss E, Bleich M, Grone HJ, Nelson PJ, Schlondorff D, Cohen CD, Kretzler M: Modular activation of nuclear factor-ĸB transcriptional programs in human diabetic nephropathy. Diabetes 2006;55:2993–3003.
[PubMed]
24.
Mora C, Navarro JF: Inflammation and diabetic nephropathy. Curr Diab Rep 2006;6:463–468.
[PubMed]
25.
Christensen EI, Verroust PJ: Interstitial fibrosis: tubular hypothesis versus glomerular hypothesis. Kidney Int 2008;74:1233–1236.
[PubMed]
26.
Abbate M, Zoja C, Remuzzi G: How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006;17:2974–2984.
[PubMed]
27.
Wolf G, Ziyadeh FN: Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007;106:26–31.
[PubMed]
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.
